Ligand Pharmaceuticals Incorporated (LGND)
Largest Insider Buys in Sector
LGND Stock Price History Chart
LGND Stock Performance
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight …
Insider Activity of Ligand Pharmaceuticals Incorporated
Over the last 12 months, insiders at Ligand Pharmaceuticals Incorporated have bought $243,481 and sold $9.62M worth of Ligand Pharmaceuticals Incorporated stock.
On average, over the past 5 years, insiders at Ligand Pharmaceuticals Incorporated have bought $229,306 and sold $6.25M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Davis Todd C (Chief Executive Officer) — $486,961.
The last purchase of 2,500 shares for transaction amount of $243,481 was made by Davis Todd C (Chief Executive Officer) on 2024‑08‑08.
List of Insider Buy and Sell Transactions, Ligand Pharmaceuticals Incorporated
| 2024-09-23 | Sale | President & COO | 9,772 0.0543% | $101.22 | $989,121 | +4.28% | ||
| 2024-09-23 | Sale | CLO & Secretary | 2,000 0.0109% | $99.60 | $199,201 | +4.28% | ||
| 2024-09-20 | Sale | President & COO | 6,275 0.0348% | $104.10 | $653,238 | +0.64% | ||
| 2024-09-20 | Sale | Chief Financial Officer | 1,275 0.0071% | $103.94 | $132,518 | +0.64% | ||
| 2024-08-28 | Sale | CLO & Secretary | 1,500 0.0082% | $106.39 | $159,591 | -2.99% | ||
| 2024-08-26 | Sale | President & COO | 11,389 0.0626% | $105.61 | $1.2M | -1.55% | ||
| 2024-08-23 | Sale | President & COO | 6,312 0.0349% | $104.80 | $661,479 | -0.13% | ||
| 2024-08-22 | Sale | President & COO | 1,157 0.0065% | $105.54 | $122,110 | +0.13% | ||
| 2024-08-09 | Sale | President & COO | 18,245 0.0999% | $98.50 | $1.8M | +3.51% | ||
| 2024-08-08 | Chief Executive Officer | 2,500 0.014% | $97.39 | $243,481 | +6.94% | |||
| 2024-05-17 | Sale | Chief Financial Officer | 5,156 0.0289% | $86.66 | $446,844 | +17.84% | ||
| 2024-05-16 | Sale | Chief Financial Officer | 2,264 0.0126% | $86.00 | $194,712 | +19.23% | ||
| 2024-05-15 | Sale | Chief Financial Officer | 5,873 0.0328% | $86.01 | $505,148 | +17.88% | ||
| 2024-05-14 | Sale | President & Chief Operating | 14,158 0.0786% | $85.10 | $1.2M | +18.34% | ||
| 2024-05-13 | Sale | President & Chief Operating | 3,440 0.0193% | $84.54 | $290,828 | +19.99% | ||
| 2024-05-09 | Sale | Chief Legal Officer & | 10,000 0.0537% | $83.04 | $830,449 | +16.91% | ||
| 2024-05-09 | Sale | director | 934 0.005% | $83.20 | $77,713 | +16.91% | ||
| 2024-03-05 | Sale | director | 1,893 0.0108% | $74.30 | $140,650 | +16.07% | ||
| 2024-02-28 | Sale | Chief Financial Officer | 140 0.0008% | $88.46 | $12,384 | +1.47% | ||
| 2023-09-22 | CHIEF EXECUTIVE OFFICER | 4,000 0.0232% | $59.38 | $237,529 | +24.41% |
Insider Historical Profitability
| Davis Todd C | Chief Executive Officer | 123010 0.6733% | $115.62 | 3 | 7 | +24.73% |
| Sabba Stephen L | director | 28926 0.1583% | $115.62 | 3 | 6 | +53.3% |
| Loeb Daniel S | 2027378 11.0974% | $115.62 | 2 | 1 | <0.0001% | |
| HIGGINS JOHN L | director | 422984 2.3153% | $115.62 | 7 | 25 | +13.79% |
| FOEHR MATTHEW W | President and COO | 173354 0.9489% | $115.62 | 7 | 13 | +42.46% |
Institutional Investor Ownership
| BlackRock | $209.67M | 15.97 | 2.87M | -3.17% | -$6.87M | 0.01 | |
| The Vanguard Group | $137.73M | 10.49 | 1.88M | +0.41% | +$555,413.80 | <0.01 | |
| Macquarie Group | $75.53M | 5.75 | 1.03M | +4.64% | +$3.35M | 0.07 | |
| Janus Henderson | $73.72M | 5.61 | 1.01M | -24.92% | -$24.46M | 0.04 | |
| Stephens Investment Management Group LLC | $50.93M | 3.88 | 696,758 | +5.66% | +$2.73M | 0.68 |